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Abstract
Background: Studies in South-East Asia have suggested that early diagnosis and treatment with artesunate (AS)
and mefloquine (MQ) combination therapy may reduce the transmission of Plasmodium falciparum malaria and the
progression of MQ resistance.
Methods: The effectiveness of a fixed-dose combination of AS and MQ (ASMQ) in reducing malaria transmission
was tested in isolated communities of the Juruá valley in the Amazon region.
Priority municipalities within the Brazilian Legal Amazon area were selected according to pre-specified criteria.
Routine national malaria control programmatic procedures were followed. Existing health structures were reinforced
and health care workers were trained to treat with ASMQ all confirmed falciparum malaria cases that match
inclusion criteria. A local pharmacovigilance structure was implemented. Incidence of malaria and hospitalizations
were recorded two years before, during, and after the fixed-dose ASMQ intervention. In total, between July 2006
and December 2008, 23,845 patients received ASMQ. Two statistical modelling approaches were applied to monthly
time series of P. falciparum malaria incidence rates, P. falciparum/Plasmodium vivax infection ratio, and malaria
hospital admissions rates. All the time series ranged from January 2004 to December 2008, whilst the intervention
period span from July 2006 to December 2008.
Results: The ASMQ intervention had a highly significant impact on the mean level of each time series, adjusted for
trend and season, of 0.34 (95%CI 0.20 – 0.58) for the P. falciparum malaria incidence rates, 0.67 (95%CI 0.50 – 0.89)
for the P. falciparum/P. vivax infection ratio, and 0.53 (95%CI 0.41 – 0.69) for the hospital admission rates. There was
also a significant change in the seasonal (or monthly) pattern of the time series before and after intervention, with
the elimination of the malaria seasonal peak in the rainy months of the years following the introduction of ASMQ.
No serious adverse events relating to the use of fixed-dose ASMQ were reported.
Conclusions: In the remote region of the Juruá valley, the early detection of malaria by health care workers and
treatment with fixed-dose ASMQ was feasible and efficacious, and significantly reduced the incidence and
morbidity of P. falciparum malaria.
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Background
Artemisinin-based combination therapy (ACT) is con-
sidered the best available treatment for uncomplicated
Plasmodium falciparum malaria, and is at the heart of
the global strategy for malaria control [1]. One of the
better documented form of ACT is that combining arte-
sunate (AS) and mefloquine (MQ)(ASMQ) [2].
The use of ASMQ was considered in Asia as a strategy
to mitigate resurgence of malaria and the intensifying
spread of anti-malarial drug resistance well before the
World Health Organization (WHO) recommended using
ACT. Over the last 20 years, in the low transmission
areas of the Thai Burmese border, the combination of
AS and MQ has shown high efficacy and has been of
great benefit in considerably reducing the transmission
of multidrug resistant malaria, as well as reversing the
trend of increasing MQ resistance. [2-8].
Safe, rapid, and reliably effective, the combination of AS
and MQ is one of five forms of ACT currently recom-
mended by the WHO as a first-line anti-malarial treat-
ment. The WHO also recommends that fixed-dose
combinations (FDC) be used whenever possible [1] to in-
crease compliance to treatment. In 2002, in order to ad-
dress the treatment needs of people most threatened by
malaria and underscoring the need for public leadership,
the Fixed-Dose Artesunate-Based Combination Therapies
(FACT) Consortium, created by the Drugs for Neglected
Diseases initiative (DNDi) and the Special Programme for
Research and Training in Tropical Diseases (TDR), devel-
oped ASMQ as a (FDC). Within the FACT Consortium,
Farmanguinhos was the first manufacturing partner of
ASMQ FDC. By developing a FDC of well-established use,
DNDi and its partners aimed to improve treatment com-
pliance, extend its use in malaria endemic countries and
fight more efficiently against resistance development.
[9,10]. This user-friendly new tablet co-formulation, which
simplifies treatment with a single daily dose of 1 or 2
tablets for three days, represents an innovation that could
have considerable impact in the treatment of uncompli-
cated P. falciparum malaria. Fixed-dose combinations
eliminate the possibility of patients taking only one com-
ponent of the combination and are expected to improve
patient compliance[1]. With specific presentations for
children aged between 6 months and 11 years, ASMQ
FDC addresses the needs of children, the primary victims
of malaria worldwide.
In 2008, approximately 320,000 cases of P. falciparum
malaria were reported in Latin America, where Brazil
has the highest malaria burden [11]. In Brazil, 99.8 % of
malaria transmission occurs in eight states (Acre,
Amapá, Amazonas, Mato Grosso, Pará, Rondônia, Ror-
aima, Tocantins and part of Maranhão) that together
form the Legal Amazon [12]. With a mean incidence of
500,000 cases/year, malaria affects all age groups equally,
except individuals below one year and older than 60 years
of age, for whom incidence is lower. Transmission
increases during the seasonal peak, when climatic condi-
tions are favourable to vector proliferation. New urban
growth has been related to malaria burden in cities, such
as Cruzeiro do Sul [12]. A decrease in malaria cases was
observed as of 2006, which has been related to several
factors, namely the introduction of ACT for P. falcip-
arum malaria treatment, greater investments, capacity
building on prevention and control, and epidemiologic
data analyses, which allow a focus on malaria burdens in
real time, both from decision makers and the popula-
tions involved [12]. Malaria risk in Brazil is classified
according to the Annual Parasite Incidence (API). High
risk areas have an API of ≥50/1000 inhabitants, inter-
mediate areas of 10–49/1000 inhabitants, and low risk
areas have an API <10/1000 inhabitants. From 2003–
2007, in the Acre, Amazonas and Roraima states of the
Legal Amazon, 79 municipalities were classified as high
risk, including eleven with an API >300/1000 inhabi-
tants, three of which were areas in the Juruá valley of
the Acre State included in the present study: Rodrigues
Alves, Mâncio Lima and Cruzeiro do Sul (Figure 1).
Efficacy studies initiated by the Amazon Network for
the Surveillance of Antimalarial Drug Resistance (RAV-
REDA), created in 2001 to monitor Plasmodium resist-
ance, showed cure rates below 90 % for quinine sulphate
and doxycycline (at the time, the first-line regimen) for
P. falciparum treatment, and prompted the introduction
of ACT in 2006 by the National Malaria Control
Programme (PNCM). Chloroquine and primaquine
0,50 mg base/kg during seven days remain the treatment
for P. vivax malaria [13].
This article presents the results of a phase IV deploy-
ment study investigating the impact of fixed-dose
ASMQ combination on P. falciparum incidence, P. vivax
and P. falciparum ratio, and on the number of hospital
admissions in three municipalities in the Amazon Basin
(Brazil), characterized by high malaria incidence and
concerns of increasing anti-malarial resistance to quin-
ine-doxycycline. The study aimed to assess the suitability
of replacing quinine sulphate and doxycycline as a na-
tional first-line treatment policy for children and adults
with uncomplicated P. falciparum malaria in Latin
America. This study is the largest to date on the pro-
grammatic use of ASMQ in Latin America.
Study area description and population selection
The study included data collected between July 2004
and December 2008. The ASMQ intervention was car-
ried out between July 2006 and December 2008 in three
municipalities in the Juruá valley, within the state of
Acre in Brazil: Cruzeiro do Sul, Mancio Lima and Rodri-
gues Alves (Figure 1). The municipalities were selected
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because they had recorded more than 20 P. falciparum
malaria cases per month between 2003 and 2004, and
had a stable population (defined by < 15 % proportion of
imported cases), as well as supportive and cooperative
local health authorities.
Acre state, situated in the most occidental region of
Legal Amazon (Figure 1) has a population of 680,073
inhabitants; 15.2 % (103,371) of the population live in
Cruzeiro do Sul, Mâncio Lima and Rodrigues Alves, and
account for 86 % of Acre’s malaria cases. The state of
Acre has a tropical climate, with temperatures ranging
between 22–34 °C (72–93 °F), relative humidity of 60–
85 %, and a rainy season that lasts from October
through to April.
Malaria epidemiology in Acre
Anti-malarial drug resistance has not been investigated
in this region for almost two decades [14,15]. Acre bor-
ders Peru and Bolivia, where until recently first-line
treatment regimens for P. falciparum malaria differed
from those used in Brazil [13,16,17]. As a result, sus-
tained population influx from these countries may affect
the local patterns of drug-resistance [14,15].
Malaria incidence in some areas of the Amazon Basin
rose between 2003 and 2005, which was attributed to
several environmental and socio-economic factors, in-
cluding climatic changes, new urban growth, cattle
ranching and agricultural practices associated with de-
forestation) [16,18]. Public health strategies promoted by
the PNCM were not fully implemented. The Ministry of
Health initiated a collaborative task force of health man-
agers in the Amazon region to coordinate population
movements and to prioritize malaria surveillance, pre-
vention and control[12,19].
In the Juruá Valley of Acre, Brazil, P. vivax predomi-
nates in urban populations, but in 2009, P. falciparum
still accounted for more than half of the malaria burden
in isolated river communities [16].
The most important malaria vector in Brazilian endemic
areas is Anopheles darlingi, and the most vulnerable group
consists of low-income workers (fishermen and gold
miners) [20-22]. Anopheles darlingi is the main species
captured outside and inside the homes of inhabitants of
the Juruá valley, in a proportion of 4:1, respectively. The
mean rate of An. darlingi per person/hour was 3.2 indoors
and 11.5 outdoors. Both inside and outside feeding prefer-
ences are from ~8:00 p.m. until ~0:00 a.m. (Izanelda
Magalhães, personal communication).
Malaria and vector control programme
The control strategy of the Brazilian National Malaria
Control Programme (Programa Nacional de Controle da
Malária, PNCM) is based on early diagnosis and treat-
ment, selective vector control interventions, early epi-
demic detection and involvement of local government and
concerned populations. Malaria is diagnosed by rapid tests
based on the immunochromatographic method or
Giemsa-stained thick blood smears, according to PNCM
Figure 1 Location of the study area.
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training recommendations and quality control guidelines.
Malaria treatment in Brazil is free of charge, as per gov-
ernment policy.
In 2000, malaria control programmes were decentra-
lized to individual states of Brazil. In Acre state, as 90 %
of total cases of malaria occur in the Juruá valley, a re-
gional coordination body for malaria control was created.
This organization includes support teams (diagnosis, epi-
demiology, vector control, health education and social
mobilization), information systems as well as administra-
tive and pharmaceutical assistance. In November 2005,
intensified malaria control activities included active sys-
tematic screening of the population as routine practice,
with weekly screenings performed by healthcare workers.
Health surveillance workers in each locality collected
thick blood smears, administered therapy and provided
health education. These agents also prevented prescrip-
tion mistakes and sought to improve treatment compli-
ance. Local health facilities supported diagnosis and drug
distribution. Drug supply was planned according to the
number of cases reported for each type of malaria infec-
tion (P. falciparum vs. P. vivax). The Brazilian Ministry
of Health regulated drug distribution and provided
epidemiological data by mapping drugs received, distrib-
uted, and consumed.
By 2006–2007, the studied municipalities had a net-
work of 73 diagnostic laboratories, 475 health surveil-
lance workers, and 229 hospital beds. The private sector
was also involved. Control strategy results were moni-
tored by the Epidemiological Surveillance Information
System Malaria module online database (SIVEP-malaria).
Epidemiological and service indicators were evaluated
on a weekly basis by the management team and all
supervisors, ensuring that all information was dissemi-
nated widely.
Vector control strategies included outdoor thermo-
nebulization and indoor chemical residual spraying with
cipermetrine, and environmental management of larvae
control until 2006. Biolarvicide was used in water tanks
from December 2005 to July 2007. As of October 2006,
the strategy focused mainly on vector control, with the
goal of using indoor chemical spraying in 80 % of the
highest risk area homes. In December 2007, an interven-
tion with long lasting impregnated bed nets was
initiated, where 7,000 insecticide-treated bed nets were
distributed to cover 100 % of the population in 13 local-
ities selected on the basis of epidemiological criteria:
high disease burden, high proportion of P. falciparum
infections, population age range, continuous access to
treatment and diagnosis, good management of informa-
tion systems, evidence of transmission inside the homes,
and acceptability of bed nets to the population. These
localities also had the least reduction in malaria inci-
dence in previous years compared with other localities
in the Juruá valley. Adequate anti-malarial drug control
and supplies were available through the cooperation of
health authorities and malaria control programs.
Methods
The study was designed as an open-labelled, community-
based intervention study in three municipalities of Acre
state. These municipalities contained 73 localities, as noti-
fication units with laboratory and drug supply capabilities.
The study included data collected routinely through the
national surveillance system, SIVEP-malaria, between July
2004 and December 2008. The ASMQ intervention was
initiated on July 2006, with completion on December
2008. The population within these municipalities was
compared pre- and post-ASMQ intervention.
Inclusion and exclusion criteria
All patients aged ≥6 months with an uncomplicated P.
falciparum infection diagnosis, confirmed by thick smear
enrolled in the public health system of the intervention
municipalities were eligible for the study. The exclusion
criteria were pregnancy and presence of clinical danger
signs and other clinical features of severe malaria [23].
Treatments and study procedures
There were no restrictions to the use of other medica-
tions, except for other anti-malarials and drugs with
known interaction. Prior to study initiation, malaria
health workers were trained in order to prevent uncon-
trolled use of other anti-malarials in the study areas.
Special attention was paid to MQ single tablet therapy,
which is no longer recommended and has been with-
drawn from Acre state. Standard treatment with quinine,
doxycycline or primaquine was available in case patients
declined trial participation.
Participating subjects who met the inclusion criteria
were treated with FDC ASMQ (manufactured by Farma-
guinhos), according to age, using either a low dose (LD)
tablet 25 + 50 mg (25 mg of artesunate and 50 mg of
mefloquine base, as 55 mg mefloquine hydrochloride) or
a high dose (HD) tablet: 100 + 200 mg (100 mg of arte-
sunate and 200 mg of mefloquine base, as 220 mg of
mefloquine hydrochloride).
Dosing was daily for 3 days and stratified by age: (i) 6–
11 months of age: 1 ASMQ LD tablet, (ii) 1–6 years of
age: 2 LD ASMQ tablets, (iii) 7–13 years of age: 1 HD
tablet, and iv) 14 years of age and older: 2 HD tablets.
Most of the time, treatment was directly observed, but
for patients living in remote areas, only the first dose
was directly observed and the remainder of the treat-
ment was taken home. At study entry, diagnoses were
performed by rapid test or thick smears, and patients
were enrolled on the basis of a positive result. During
the study period, rapid tests were performed in remote
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areas, but slides were collected to confirm the result by
thick smear.
During the first six months of the study, samples of
positive and negative malaria smears from every micro-
scope technician were reread in blinded conditions for
quality control, according to PNCM standard oper-
ational procedures. From November 2006, every positive
only P. falciparum slide was revised, identified by a
SIVEP number and filed under the month and notifica-
tion area. As a routine procedure, 10 % of negative slides
were re-examined. When conflicting results occurred,
which was less than 1 % of cases, the microscopy techni-
cian was advised to attend a training programme.
The procedure to identify double entries and cure-
verifying slides used the RecLink software duplicity routine
[24,25] that generates a unique code for every individual.
In order to improve software performance, records must
be of good quality; therefore, the RecLink routine was
alternated with manual verification procedures and
repeated about 30 times. Every patient had the earliest
positive slide defined as diagnosis date, and any slide be-
tween day 7 and day 40 after diagnosis was considered a
follow-up slide.
Safety evaluation
Adverse events monitoring was done by spontaneous
reporting through the local pharmacovigilance system.
In order to record these events, standard national regu-
latory agency forms were made available at the health fa-
cilities, diagnosis posts, and to every health surveillance
agent.
Ethical approval
The study was approved by the São Paulo University
Ethics Committee. Participation in the study was entirely
voluntary. Patients were informed of the risks and bene-
fits relating to the study, and participants could with-
draw from the study at any time. Written informed
consent was obtained from all literate patients or guar-
dians. Illiterate patients or guardians recorded their con-
sent with a thumbprint. A witness confirmed both types
of consent. Before starting the study, a state health team
visited the communities involved to describe study
objectives and methods. Communities and local health-
care providers also gave approval.
Statistical analysis
In order to address the impact of the introduction of
ASMQ in the Juruá valley region, three outcome vari-
ables were analysed: monthly incidence rates of P. falcip-
arum malaria, the ratio between monthly incidences of
P. falciparum and P. vivax malaria, and the monthly
hospital admission rates due to malaria (ICD-10: B58 to
B54). The period of analysis ranged from January 2004
to December 2008 (before and after introduction of
FDC ASMQ).
Because the time series spanned five years, and the
outcome variables were based on monthly incidence of
the disease, the model had to take into account the
effects of trend and seasonality.
The effect of ASMQ on the mean level of each out-
come time series was evaluated in terms of main effects
and interactions. Three main effects were evaluated,
years, months and intervention, whilst the interaction
involved intervention and months. The model, therefore,
contemplated the time trend based on indicator vari-
ables for years and seasonality, with indicator variables
for months, and the intervention impact with an indica-
tor variable for the whole period after the introduction
of ASMQ.
For each outcome variable two models were fitted: (a)
only main effects of years, months and the intervention;
and (b) the same main effects with the addition of an
interaction between months and intervention. Hence,
regarding the intervention, the first model exploits its ef-
fect adjusted for trend and seasonality, whereas the sec-
ond model exploits its effect on if and how the
intervention affected the seasonal pattern of the time
series. The two models therefore evaluate different
aspects of the intervention. The full model specification
is presented in the expression below:
log Yij
  ¼ β0 þ offset þ βiMi þ γ jAj þ αI ASMQf g
þ δiMiI ASMQf g
Where Yij : i ¼ 1; . . . ; 12; j ¼ 2004; . . . ; 2008
 
is the
outcome time series, Mi : i 6¼ 7f g are month indicator
variables, Aj : j > 2004
 
are year indicator variables,
I ASMQf g is the intervention indicator variable, β0 is a com-
mon intercept or the baseline (here July 2004), βi : i 6¼ 7
 
are the monthly effects, γi : i 6¼ 7f g are the yearly effects,
α is the intervention effect, and δi : i 6¼ 7f g are the inter-
action effects between months and intervention. The offset
was either the logarithm of the at risk population for rates,
or the incidence of P. vivax malaria for the P. falciparum/
P. vivax ratio.
The above is the expression for the second modelling
approach. To obtain the expression for the first ap-
proach the interaction terms should be dropped from
the formula.
As July 2006 was the first month after the start of the
intervention, the month of July was chosen as the refer-
ence for the monthly pattern. 2004 was selected as the
baseline year, as it represents pre-epidemic and pre-
intervention levels of the time series. The intervention
was implemented in June 2006, so the intervention period
in the statistical analysis was regarded as beginning in July
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2006 and ending in December 2008. The impact of the
ASMQ intervention was assessed in comparison with the
baseline, adjusting for the effects of other years and
months. Thus, the coefficients of the remaining months
and years represent the variation on the log-incidence
rates in comparison to July 2004. The monthly counts
were analysed and the model parameters estimated
according to a quasi-Poisson estimation procedure and
took into account an offset variable. Further, residual diag-
nostics were performed for each of the six adjusted
models.
The two modelling approaches are presented as they
address different questions;
- the main effect model establishes that the interven-
tion had an effect on the mean level of the time series,
- whereas the main effect + interaction model estab-
lishes if the intervention had an effect on the monthly
pattern (seasonality) of the time series, hence altering
the mean level of the time series, albeit indirectly.
Data were analysed using the following software: Tab-
leau 3.5, Microsoft Office Excel 2003, RecLink, and the
R (R Development Core Team 2011) version 2.11.
Results
Description of population
The total population who received ASMQ between July
2006 and December 2008 amounted to 23,845 subjects
in the Cruzeiro do Sul, Mancio Lima and Rodrigues
Alves districts. The total population at risk in the three
municipalities ranged from 96,496 to 103,799 between
2006 and 2008. The proportion of female participants
was 43 %. There was no significant change in the total
population of the different study municipalities in the
Juruá valley during the observed period (January 2004 to
December 2008). Over the intervention period, the
yearly distribution of ASMQ-treated subjects living in
the Juruá valley stratified by age showed that the major-
ity (62.6 %) were aged 14 and over (Table 1).
Plasmodium falciparum incidence rates and efficacy
evaluation
The P. falciparum malaria cumulative incidence rates
(per 10,000 inhabitants) over one year were stratified by
age range in the Juruá valley (Table 2). Following the
introduction of ASMQ treatment in 2006, a large
decrease in the P. falciparum yearly incidence was
observed across all age groups of subjects living in the
study area. The P. falciparum malaria incidence rate had
sharply increased in the Juruá valley during the second
half of 2005, with an epidemic peak at the beginning of
2006 before the introduction of ASMQ treatment
(Figure 2a).
Monthly incidence of P. falciparum malaria increased
steadily over the first half of the study period, with a
subsequent steady decline (Figure 2a). The peak P. fal-
ciparum malaria incidence occurred a few months be-
fore the introduction of FDC ASMQ therapy. The P.
falciparum/P. vivax ratio increased in the same period
up to the initiation of intervention, when there was a
sharp drop (Figure 2b). The peak P. falciparum/P. vivax
ratio coincided with the month of introduction of
ASMQ. The pattern of malaria hospital admission rates
represents a mix of the previous two series, however
with a substantial reduction in the mean level at the end
of the study period (Figure 2c).
Model parameter estimates transformed to the original
scale are presented in Additional file 1, namely rate
ratios in the case of incidence and hospital admissions,
and ratios in the case of the P. falciparum/P. vivax ratio.
Mutually adjusted increases (decreases) on the mean
levels of the outcome are shown for a given month, year
or intervention period. The different columns represent
the adjusted model according to what was described in
the methods section, thus six models altogether, two for
each outcome. The two first columns correspond to in-
cidence rates, the next two to the P. falciparum/P. vivax
ratio, and the last two to hospital admission rates. Under
each outcome, the first column shows results based on
the first approach (main effects) whilst the second col-
umn presents results of the second approach (main
effects and interactions). In order to address the differ-
ence between both approaches, the number of para-
meters fitted under each model and its quasi-deviance
statistics are shown at the bottom of the table.
There was a significant decrease in the mean level of
the time series for the three outcomes after the intro-
duction of ASMQ, namely 0.34 (95%CI 0.20 – 0.58),
0.67 (95%CI 0.50 – 0.89), and 0.53 (95%CI 0.41 – 0.69)
Table 1 Yearly distribution of ASMQ-treated subjects in
the Juruá valley stratified by age
<1 year 1 to 6 years 7 to 13 years ≥14 years
2006 86 (0.7 %) 2,114 (17.4 %) 2,333 (19.2 %) 7,682 (62.7 %)
2007 72 (0.9 %) 1,303 (16.3 %) 1,569 (19.6 %) 5057 (63.2 %)
2008 38 (1.1 %) 667 (18.5 %) 698 (19.4 %) 2,195 (61.0 %)
Total 196 (0.8%) 4,084 (17.2%) 4,600 (19.4%) 14,880 (62.6%)
Table 2 Plasmodium falciparum incidence rates (per
10,000 inhabitants) stratified by age (Juruá valley)
Year (population
at risk)
<1 year 1 to 6
years
7 to 13
years
≥14
years
2004 (96496) 5.58 56.43 55.56 60.22
2005 (106882) 22.64 148.58 161.81 164.33
2006 (109827) 67.95 298.59 327.63 307.84
2007 (112755) 22.88 68.15 79.64 71.44
2008 (103799) 13.38 38.58 38.01 33.61
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for incidence rates of P. falciparum, the P. falciparum/P.
vivax ratio, and for malaria hospital admission rates, re-
spectively. These results are adjusted for trend and sea-
sonality (i.e. under the first modelling approach). It is
important to notice the yearly effects pattern: for P. fal-
ciparum malaria incidence rates, 2005, 2006, and 2007
had significantly higher levels than 2004, whereas in
2008 there was no significant increase or decrease com-
pared to 2004; for the P. falciparum/P. vivax ratio, 2006
had a significantly higher level than 2004; and for mal-
aria hospital admission rates, 2005 and 2006 had signifi-
cantly higher levels than 2004, but 2008 had significantly
lower levels than 2004. In all outcomes, there was no
statistically significant effect for months.
In addition, there was a marked change in the sea-
sonal pattern of all three outcomes (i.e., under the sec-
ond modelling approach). The incidence rates in the
months of November (3.87, 95%CI 1.82 – 8.22) and
December (4.50, 95%CI 2.14 – 9.46) before the inter-
vention showed increases compared to July, whereas
there were decreases of 0.74 (95%CI 0.42 – 1.32) for
November and of 0.56 (95%CI 0.30 – 1.05) for Decem-
ber, after the intervention. A similar picture emerged
for the P. falciparum/P. vivax ratio regarding the
months of October, November, and December. It is im-
portant to notice that usually October marks the begin-
ning of the rainy season in the Juruá valley region
(Additional file 1).
Figure 2 Incidence rate of P. falciparum malaria (a), P. falciparum/P. vivax ratio (b), and hospital admissions (c) due to malaria in the
Juruá valley between 2004 and 2008.
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Figure 3 shows the yearly effects for the three out-
comes. Compared to 2004, the annual effect of the in-
cidence rate of P. falciparum is statistically significant
for every year except 2008, suggesting a return to pre-
epidemic levels (Figure 3a). Regarding the P. falcip-
arum/P. vivax ratio, Figure 3b shows that in 2007 the
yearly effect of this outcome had returned to pre-
epidemic levels. Finally, Figure 3c shows a marked and
significant decrease in the yearly effect of malaria hos-
pital admissions from 2007 onwards, suggesting that
the intervention may have had a greater impact for
this outcome.
Figure 4 shows the observed and predicted values for
the three outcomes, under the different statistical
approaches. Clearly under the second approach the
models adjust more closely to the observed data, there-
fore justifying the inclusion of interaction between
months and intervention.
Safety evaluation
No serious adverse events, including deaths, relating to
the use of fixed-dose ASMQ were reported. A single
non-serious adverse report was recorded in 2007 in a
seven-year old patient who experienced dizziness and
vomiting, which are adverse events associated with MQ.
Patient exposures were pooled from the SIVEP-malaria
database. No direct adverse event reports were made to
the toll-free pharmacovigilance telephone number for
Farmanguinhos or to the national regulatory agency,
ANVISA.
Figure 3 Yearly effect under the interaction model for incidence rate of P. falciparum malaria (a), P. falciparum/P. vivax ratio (b), and
malaria hospital admissions (c) in the Juruá valley between 2004 and 2008.
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Discussion
This intervention study is one of the largest successful
trial implementations in a programmatic context in
Latin America, and was performed in full collaboration
with the Ministry of Health, both at the national and
local levels, and the Pan-American Health Organization
(PAHO). The study strengthened the local health man-
agement system in Acre state and showed that it is feas-
ible to extend early malaria diagnosis and provide
adequate treatment to remote communities. The positive
effect of ASMQ was seen both in terms of malaria inci-
dence and malaria-related hospital admission rates.
FDC ASMQ was assessed in the Juruá valley, an area
with one of the highest incidences of P. falciparum malaria
in Brazil. Indeed, prior to the intervention, the P. falcip-
arum malaria incidence rate had increased dramatically
during the second half of 2005, with an epidemic peak at
the beginning of 2006 and the beginnings of a decline
when ASMQ was introduced in June 2006. Various rea-
sons were considered for the increase in P. falciparum
malaria incidence in the Juruá valley during this period, in-
cluding issues related to local malaria control manage-
ment, vector control activities and decreased efficacy of the
standard anti-malarial regimen (quinine and doxycycline).
Figure 4 Observed and predicted values under the main effects (ME) and the main effects and interactions models for incidence rate
of P. falciparum malaria (a), P. falciparum/P. vivax ratio (b), and malaria hospital admissions (c) in the Juruá valley between 2004 and
2008. (a).
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When using 2004 as the baseline, pre-epidemic refer-
ence year, our results show P. falciparum malaria inci-
dence rates returned to pre-epidemic levels by December
2008, preceded in 2007 by the P. falciparum/P. vivax ratio
and hospital admission rates. ASMQ yielded a significant
difference in the seasonal pattern of P. falciparum inci-
dence rates, by eliminating the rainy season increase.
The P. falciparum/P. vivax ratio returned to pre-
epidemic levels (2004) in the year immediately following
the intervention (2007), before a fall in the cumulative
incidence of P. falciparum cases, suggesting that the P.
falciparum/P. vivax ratio may be more sensitive and spe-
cific than P. falciparum incidence alone as an epidemio-
logical marker in areas of mixed transmission.
Data analyses were clouded because ASMQ was intro-
duced in the declining phase of a steady malaria epidemic,
after some 18 months, and in areas where vector control
activities had been increased. Nevertheless, elimination of
the seasonal peak and a significant decline in hospital ad-
mission rates are important and our data suggest ASMQ
was the major contributor to these observations. A signifi-
cant decline in severe malaria hospitalizations and malaria
incidence were also documented in South Africa and on
the Thai Burmese border following the deployment of
artemether-lumefantrine and non-fixed ASMQ, respect-
ively [6,26-28].
The inversion of the P. falciparum/P. vivax ratio is
considered a key epidemiological indicator, as a signal of
ACT activity and its potential impact on malaria mortal-
ity and morbidity. As the MQ dose is divided in three
equal parts in the fixed-dose combination, it is expected
that the fixed dose would have a better tolerability than
non-fixed AS +MQ. A decrease in early vomiting with
the new fixed-dose formulation has been previously
reported [29]. Our study confirmed the good safety and
tolerability profile of the combination. No serious or sig-
nificant adverse events, such as convulsions or acute
psychiatric emergencies were reported. One mild ad-
verse event of dizziness and vomiting was transient,
without the necessity for further intervention. The phar-
macovigilance system described here was adapted to a
rural setting, was simple, and relied on the passive de-
tection of drug side effects, so lacked sensitivity, with
consequential underreporting. The reporting of adverse
events was emphasized during training of health workers
and in informative leaflets. The low rate of reported side
effects was attributed by the health workers to previous
treatment with quinine, doxycycline and primaquine,
whereby the population had grown accustomed to the
frequent nausea and tinnitus associated with quinine. As
the new fixed-dose ASMQ combination had better toler-
ability, it is thought that patients were less inclined to
complain. Further data on safety in this area will be col-
lected in the post-marketing setting (Farmanguinhos).
Studies have also shown that a fixed-dose ASMQ com-
bination has improved bioavailability, compared to split-
dose regimens [29], a beneficial pharmacokinetic effect for
reducing the probability of developing de novo resistance.
Moreover, the fixed-dose formulation may translate clinic-
ally into better compliance, thereby further contributing
to limiting the development of drug resistance.
In areas with low levels of MQ resistance, initial
recommendations by the WHO quoted lower doses of
MQ in combination with an artemisinin drug, but based
on pharmacokinetic and pharmacodynamic modelling
data, it is now believed that MQ should be used at a dose
of 25 mg/kg. Indeed, it was shown that initial use of a
15 mg/kg dose provided a greater opportunity for selection
of resistant mutations and could thus lead more rapidly to
resistance than using a dose of 25 mg/kg [30].
This phase IV deployment study had the intrinsic limi-
tation of not being a randomized comparative study ver-
sus the current standard of care. However, our results
show that FDC ASMQ represents an advance over the
poorly tolerated and lengthy 7-day regimen of quinine
and doxycycline.
Conclusion
The fixed-dose ASMQ formulation was developed with
the aim of addressing the treatment needs of those at
risk of malaria, with ease of administration and a poten-
tial for improved treatment compliance. Based on con-
vincing efficacy and safety data, this new product may
have a considerable impact in the treatment of uncom-
plicated P. falciparum malaria in Latin America. The im-
pact of this intervention was seen rapidly. The study
strengthened the local health management system in the
state of Acre and showed that extending early malaria
diagnosis and providing adequate treatment to remote
communities is feasible.
These results further support large-scale use of fixed-
dose ASMQ and of ACT in general, a strategy that has
shown similar results in other regions [26,27] and is
recommended in all endemic regions to circumvent the
spread of P. falciparum drug resistance and to reduce
the impact of malaria [1].
Based on the data presented here, fixed-dose ASMQ
was launched on a national scale. Ongoing investigations
include continued pharmacovigilance monitoring, stud-
ies of ASMQ in pregnancy and an evaluation of ACT for
the treatment of P. vivax malaria.
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